COMMUNIQUÉS West-GlobeNewswire
-
Onco360® Has Been Selected as a National Pharmacy Partner for PIMJETMI® (pimicotinib)
18/11/2026 -
His Choice Health Announces No Needle No Scalpel Vasectomy Clinic In Greenville, SC Opening January 7, 2027
18/11/2026 -
MEDIROM Announces Receipt of Nasdaq Delisting Notice, Filing of Annual Report and Submission of Hearing Request
18/11/2026 -
Palvella Therapeutics to Host Webcast to Introduce New QTORIN™ Program
18/11/2026 -
Teva Announces R&D Leadership Transition; Eric Hughes to Depart the Company
18/11/2026 -
Communiqué de presse : Infilbray, de Sanofi, approuvé aux États-Unis comme le premier médicament indiqué dans le traitement des manifestations neurologiques de la maladie de Gaucher de type 3
18/11/2026 -
Press Release: Sanofi’s Infilbray approved in the US as the first medicine to treat neurological manifestations of Type 3 Gaucher disease
18/11/2026 -
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
18/11/2026 -
New Three-Year Real-World LEQEMBI® Data Presented at CTAD 2026
18/11/2026 -
SHARP Surgery Center Opens Four-Room Ambulatory Surgery Center in Austin Built Around the SHARP Method
18/11/2026 -
PRF or PRP Hair Treatment: What Actually Separates the Two Platelet Preparations, and Why Patients Are Rarely Told Which One They Receive
18/11/2026 -
Quantum-Si Achieves Historic Milestone in Protein Sequencing with Single-Molecule Detection of All 20 Amino Acids on Proteus™
18/11/2026 -
Enlivex Announces Positive Interim DSMB Safety Review, Supporting Continued Enrollment in Phase IIb Knee Osteoarthritis Trial
18/11/2026 -
Actuate Therapeutics Reports Positive Monotherapy Data in Aggressive Melanoma Preclinical Model with Daily Dosing of Elraglusib Oral Tablet at ENA 2026
18/11/2026 -
Retension Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
18/11/2026 -
Telomir Pharmaceuticals Selects Linical to Advance FDA-Cleared Phase 1/2 Clinical Trial of Telomir-Zn in Triple-Negative Breast Cancer
18/11/2026 -
Scribe Therapeutics Presents New Data Advancing the Potential of Ultra-Long-Acting Genetic Medicines for Cardiovascular Disease at AHA Scientific Sessions 2026
18/11/2026 -
Iambic Presents Preclinical Data for CDK2/4 Inhibitor IAM-C1 and Brain-Penetrant KIF18A Inhibitor IAM217 at 2026 EORTC-NCI-AACR Symposium
18/11/2026 -
Aradigm Selects City of Hope as a Preferred National Destination for Cell and Gene Therapy
18/11/2026
Pages